Miglitol: assessment of its role in the treatment of patients with diabetes mellitus (Q33422586)

26 July 2017

1 reference

title

Miglitol: assessment of its role in the treatment of patients with diabetes mellitus (English)

1 reference

26 July 2017

L K Campbell

1

1 reference

26 July 2017

D E Baker

series ordinal

2

1 reference

26 July 2017

R K Campbell

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 November 2000

1 reference

Annals of Pharmacotherapy

26 July 2017

published in

1 reference

26 July 2017

volume

34

1 reference

26 July 2017

issue

11

1 reference

26 July 2017

page(s)

1291-1301

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

26 July 2017

cites work

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

Regulation of the absorption of dietary carbohydrate in man by two new glycosidase inhibitors

21 January 2018

1 reference

Postprandial glycemic control, hormonal effects and carbohydrate malabsorption during long-term administration of the alpha-glucosidase inhibitor miglitol

21 January 2018

1 reference

A new alpha-glucosidase inhibitor (Bay-m-1099) reduces insulin requirements with meals in insulin-dependent diabetes mellitus

21 January 2018

1 reference

The effect of two new alpha-glucosidase inhibitors on metabolic responses to a mixed meal in normal volunteers

21 January 2018

1 reference

Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.

21 January 2018

1 reference

Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.

21 January 2018

1 reference

alpha-Glucosidase inhibition by miglitol in NIDDM patients

21 January 2018

1 reference

Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?

21 January 2018

1 reference

The antiglycogenolytic action of 1-deoxynojirimycin results from a specific inhibition of the alpha-1,6-glucosidase activity of the debranching enzyme

21 January 2018

1 reference

The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?

21 January 2018

1 reference

Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus

21 January 2018

1 reference

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone

21 January 2018

1 reference

Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients

21 January 2018

1 reference

Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition

21 January 2018

1 reference

Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients

21 January 2018

1 reference

Effects of alpha-glucosidase inhibitors on mouth to caecum transit time in humans

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.19269

1 reference

26 July 2017

1 reference